Sarepta Therapeutics (NASDAQ:SRPT) Given New $100.00 Price Target at Wells Fargo & Company

Sarepta Therapeutics (NASDAQ:SRPT) had its target price decreased by investment analysts at Wells Fargo & Company from $115.00 to $100.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s price target points to a potential upside of 175.71% from the company’s current price.

Several other equities research analysts also recently issued reports on SRPT. Royal Bank of Canada decreased their price objective on shares of Sarepta Therapeutics from $87.00 to $58.00 and set a “sector perform” rating for the company in a research note on Wednesday. Piper Sandler lowered their price target on Sarepta Therapeutics from $110.00 to $70.00 and set an “overweight” rating for the company in a report on Wednesday. Deutsche Bank Aktiengesellschaft reduced their price objective on Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a research note on Wednesday, March 19th. Evercore ISI lowered Sarepta Therapeutics from an “outperform” rating to an “inline” rating and set a $50.00 target price for the company. in a research note on Thursday. Finally, Morgan Stanley dropped their target price on Sarepta Therapeutics from $182.00 to $113.00 and set an “overweight” rating on the stock in a report on Wednesday. Six investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $131.22.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $36.27 on Thursday. Sarepta Therapeutics has a one year low of $35.46 and a one year high of $173.25. The company has a 50 day moving average price of $66.84 and a 200 day moving average price of $100.86. The firm has a market capitalization of $3.56 billion, a price-to-earnings ratio of 29.02 and a beta of 0.85. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). The firm had revenue of $744.86 million for the quarter, compared to analyst estimates of $685.75 million. Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The business’s revenue was up 80.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.73 earnings per share. Sell-side analysts anticipate that Sarepta Therapeutics will post 2.67 EPS for the current year.

Insider Activity

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the sale, the director now owns 27,812 shares of the company’s stock, valued at $2,771,187.68. The trade was a 8.22 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 7.70% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Manchester Capital Management LLC grew its position in Sarepta Therapeutics by 86.6% in the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 110 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of Sarepta Therapeutics by 169.6% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 156 shares in the last quarter. Byrne Asset Management LLC acquired a new position in shares of Sarepta Therapeutics during the first quarter valued at approximately $30,000. Center for Financial Planning Inc. bought a new stake in Sarepta Therapeutics during the first quarter worth approximately $31,000. Finally, Newbridge Financial Services Group Inc. bought a new stake in Sarepta Therapeutics during the fourth quarter worth approximately $36,000. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.